Pharmacokinetics of iron isomaltoside 1000 in patients with inflammatory bowel disease

BACKGROUND: Iron isomaltoside 1000 is a novel injectable iron compound which offers potential advantages in the treatment of subjects with iron-deficiency anemia. We studied the pharmacokinetics (PK) of this novel compound in subjects with mild-to-moderate inflammatory bowel disease (IBD). METHODS:...

Descripción completa

Detalles Bibliográficos
Autores principales: Nordfjeld, Kim, Andreasen, Hans, Thomsen, Lars L
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2012
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3299547/
https://www.ncbi.nlm.nih.gov/pubmed/22419860
http://dx.doi.org/10.2147/DDDT.S30015

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3299547/
https://www.ncbi.nlm.nih.gov/pubmed/22419860
http://dx.doi.org/10.2147/DDDT.S30015

Ejemplares similares